All In Biotech

Free tool

FAERS Monitor: Carmustine

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 215000 or its brand name (Carmustine, Carmustine). Reports on generic versions are filed under their own applications.

Reports

4,156

Serious

4,089

98% of reports

Hospitalization

1,170

Death reported

1,117

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use510
  • febrile neutropenia400
  • myelodysplastic syndrome298
  • disease progression269
  • mucosal inflammation256
  • thrombocytopenia232
  • pyrexia209
  • neutropenia206
  • pneumonia199
  • drug ineffective197
  • acute myeloid leukaemia172
  • infection165
  • diarrhoea160
  • product use in unapproved indication156
  • sepsis154

Reports by year received

View as table
YearReports
200484
200554
200635
200773
200898
200992
201069
2011132
2012128
201384
201461
2015132
2016102
2017223
2018315
2019336
2020367
2021309
2022280
2023432
2024293
2025229
2026228

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,003 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
myelodysplastic syndromeSignal298106.495.330,404
acute myeloid leukaemiaSignal17256.548.79,219
mucosal inflammationSignal25650.044.312,131
febrile neutropeniaSignal40030.728.011,429
disease progressionSignal26911.510.32,585
thrombocytopeniaSignal23210.59.31,996
neutropeniaSignal2067.76.71,196
sepsisSignal1547.06.0788
infectionSignal1655.85.0650
product use in unapproved indicationSignal1563.22.7235
pneumoniaSignal1993.12.7287
pyrexiaSignal2093.12.7292
off label useSignal5102.92.7683
diarrhoea1601.31.18
drug ineffective1970.80.716

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.